

PRESS RELEASE

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended on 30th June, 2014.

- For Q1 FY 14-15 revenues were at ₹ 1,114 crores, up by 15% from ₹ 972 crores during the same period last year.
- EBITDA for Q1 FY 14-15 was at ₹ 346 crores up by 66% from ₹ 208 crores during the same period last year.
- PAT for the year (before minority interest) Q1 FY 14-15 was at ₹ 256 crores up by 72% compared to ₹ 149 crores during the same period last year.


Financial Highlights of Q1 FY15 & FY 13-14

Financial Highlights	Q1 FY15	Q1 FY14	Growth	FY14	FY13	Growth
Revenues	1,114	972	15%	4,184	3,212	30%
EBITDA	345	208	66%	952	693	37%
<i>% Revenues</i>	31%	21%		23%	22%	
PBT (after exceptional item)	349	187	87%	844	582	45%
<i>% Revenues</i>	31%	19%		20%	18%	
PAT	256	149	72%	664	435	53%
<i>% Revenues</i>	23%	15%		16%	14%	
EPS	15.1	8.8	72%	39	26	53%

Performance Highlights of Q1 FY 15

- Domestic formulation business recorded revenues of ₹ 356 crores, growing by 13%.
- International revenues grew by 36% to ₹ 733 crores. Adjusting for currency movements revenues grew by 27%.
 - Revenues from US operations recorded growth of 138%.
 - Operations in Brazil registered revenue growth of 12%.

Revenues from Europe (incl. Heumann) recorded a growth of 17%. Rest of the World including Russia & CIS operations recorded a de growth of 12%.



Business Initiatives

- During the quarter company consummated acquisition of Identified Indian Branded Formulations Business of Elder Pharmaceuticals Limited for a consideration of about ₹ 2000 cores.

About Torrent Pharma

Torrent Pharma, with an annual turnover of almost ₹ 4200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry. Torrent has a fully equipped Research Center, employing almost 600 scientists, to support the Companies operations and product pipeline for both Domestic and Overseas markets. The Companies manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.

